Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT03993379 2025-12-26

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Phase 2 Terminated

3 enrolled 7 charts

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms, Recurrence

NCT03595683 2025-12-08

Pembrolizumab and EDP1503 in Advanced Melanoma

Phase 2 Terminated

8 enrolled 10 charts

Dermatologic

Melanoma

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Phase 2 Terminated

18 enrolled

CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Phase 2 Terminated

23 enrolled 15 charts

CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05388851 2025-06-22

Education for Prevention of Melanoma in Hispanic Populations

Phase 2 Terminated

145 enrolled

Dermatologic

Melanoma

NCT04698187 2025-06-11

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Phase 2 Terminated

44 enrolled 19 charts

Dermatologic

Melanoma

NCT04830124 2025-06-10

ARTISTRY-6

Phase 2 Terminated

173 enrolled

Dermatologic

Melanoma, Neoplasms

NCT01864538 2025-05-11

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Phase 2 Terminated

11 enrolled 8 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT04629339 2025-03-13

Study of INCB086550 in Select Solid Tumors

Phase 2 Terminated

16 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis

NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 2 Terminated

205 enrolled 54 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT00560118 2025-02-14

MGFOT1

Phase 2 Terminated

12 enrolled

Dermatologic

Melanoma

NCT03991130 2025-02-06

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Terminated

6 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT04375527 2024-12-04

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Phase 2 Terminated

3 enrolled

Dermatologic

Melanoma

NCT05744128 2024-12-03

PRETZCEL

Phase 2 Terminated

3 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT05457842 2024-11-20

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

Phase 2 Terminated

1 enrolled 8 charts

BreastDermatologic

Breast Neoplasms, Melanoma

NCT04310397 2024-10-30

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Phase 2 Terminated

4 enrolled 8 charts

Dermatologic

Melanoma

NCT05012397 2024-10-17

Milademetan in Advanced/Metastatic Solid Tumors

Phase 2 Terminated

40 enrolled 13 charts

DermatologicEndocrineGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Testicular Germ Cell Tumor, Adenocarcinoma of Lung, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Adrenocortical Carcinoma, Cholangiocarcinoma

NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Phase 2 Terminated

315 enrolled 73 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

NCT00863330 2024-10-03

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

Phase 2 Terminated

14 enrolled 2 charts

Dermatologic

Melanoma

NCT03476174 2024-10-02

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

Phase 2 Terminated

1 enrolled 9 charts

Dermatologic

Melanoma

NCT05200143 2024-09-19

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Phase 2 Terminated

4 enrolled 11 charts

Dermatologic

Melanoma

NCT04768881 2024-08-23

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Phase 2 Terminated

15 enrolled 15 charts

Dermatologic

Melanoma

NCT04152863 2024-08-06

V937-011

Phase 2 Terminated

85 enrolled 19 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04924413 2024-07-03

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Phase 2 Terminated

9 enrolled

Dermatologic

Melanoma

NCT02621515 2024-05-06

CA209-322

Phase 2 Terminated

7 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05050006 2024-04-16

DELTA-1

Phase 2 Terminated

29 enrolled

Dermatologic

Melanoma

NCT02978443 2024-04-04

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Phase 2 Terminated

14 enrolled 12 charts

Dermatologic

Melanoma

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Phase 2 Terminated

1 enrolled

Dermatologic

Melanoma

NCT05060003 2024-02-20

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Phase 2 Terminated

7 enrolled 4 charts

Dermatologic

Melanoma

NCT04337931 2024-02-13

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Phase 2 Terminated

45 enrolled 14 charts

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT04785365 2023-11-21

Long-Term Follow-Up Study of Patients Receiving ATL001

Phase 2 Terminated

1 enrolled

Dermatologic

Melanoma

NCT02831933 2023-09-21

ENSIGN

Phase 2 Terminated

11 enrolled 9 charts

DermatologicThoracic

Uveal Melanoma, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT03430947 2023-09-14

RadioCoBRIM

Phase 2 Terminated

20 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02740920 2023-08-25

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

Phase 2 Terminated

9 enrolled 8 charts

Dermatologic

Melanoma

NCT04644315 2023-08-07

ALpha-T

Phase 2 Terminated

1 enrolled 5 charts

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Renal Cell, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02748564 2023-08-03

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Phase 2 Terminated

10 enrolled 13 charts

Dermatologic

Melanoma

NCT02203604 2023-07-18

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Terminated

9 enrolled 13 charts

Dermatologic

Melanoma

NCT00104884 2023-06-28

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Phase 2 Terminated

4 enrolled 4 charts

Dermatologic

Melanoma

NCT03911869 2023-05-31

POLARIS

Phase 2 Terminated

13 enrolled 55 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01995344 2023-04-20

METILDA

Phase 2 Terminated

2 enrolled

Dermatologic

Melanoma

NCT05234437 2023-04-19

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Phase 2 Terminated

1 enrolled

Dermatologic

Melanoma

NCT02054520 2023-04-18

Immunotherapy Study for Patients With Stage IV Melanoma

Phase 2 Terminated

47 enrolled 16 charts

Dermatologic

Melanoma

Clinical Trials

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

PERM

O-Mel-Inib

PORTSIDE

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Tamarack

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Pembrolizumab and EDP1503 in Advanced Melanoma

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

PAVO

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Education for Prevention of Melanoma in Hispanic Populations

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

ARTISTRY-6

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Study of INCB086550 in Select Solid Tumors

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

MGFOT1

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

PRETZCEL

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Milademetan in Advanced/Metastatic Solid Tumors

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

V937-011

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

CA209-322

DELTA-1

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Long-Term Follow-Up Study of Patients Receiving ATL001

ENSIGN

RadioCoBRIM

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

ALpha-T

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

POLARIS

METILDA

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Immunotherapy Study for Patients With Stage IV Melanoma